Dual 5-alpha-reductase inhibitor reduces BPH symptoms

Orlando, FL-A newer, novel 5-alpha-reductase inhibitor offersBPH symptom relief and improvements in urinary flow rates, according tofindings from three 2-year, multicenter, phase III trials.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria